Screening of Bone Mineral Density in Women Who Have Received Chemotherapy
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Orthopedic |
| Therapuetic Areas: | Oncology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/21/2018 |
| Start Date: | November 2006 |
| End Date: | December 2009 |
The hypothesis is that postmenopausal women who have received chemotherapy have a greater
bone loss than the same age controls. The aim of this study is to obtain baseline bone
mineral density (BMD) data on women with breast and gynecological cancers who have received
chemotherapy. By comparing the Z scores of postmenopausal women who have received
chemotherapy with age matched controls this hypothesis can be evaluated. Another goal of the
study is to compare the T-score of a Heel Bone Density Scan to the T-score of the DXA Scan to
see if there is a good correlation between peripheral and DXA scores.
bone loss than the same age controls. The aim of this study is to obtain baseline bone
mineral density (BMD) data on women with breast and gynecological cancers who have received
chemotherapy. By comparing the Z scores of postmenopausal women who have received
chemotherapy with age matched controls this hypothesis can be evaluated. Another goal of the
study is to compare the T-score of a Heel Bone Density Scan to the T-score of the DXA Scan to
see if there is a good correlation between peripheral and DXA scores.
It is generally accepted that women who develop breast cancer have an increased bone mineral
density (BMD) probably due to endogenous estrogen production. After menopause, BMD decreases
rather rapidly particularly during the first years after natural menopause. Bone loss
typically is more rapid and severe in a premature induced menopause (surgical,
chemotherapeutically, or hormonal). The bone loss appears to be more rapid and at an earlier
age which advances bone age to a greater degree than actual age. Chemotherapeutically-induced
menopause accelerates this process by an average of 10 years. GnRH agonist in premenopausal
women causes amenorrhea in >95% with associated loss of both cortical and trabecular bone. In
women undergoing ovarian ablation therapy, losses in bone mass as high as 13% have been
reported in the first year of treatment. Premenopausal women who by treatment become
amenorrheic remain amenorrheic posttreatment in the vast majority of cases. Adjuvant therapy
for cancer can exaggerate bone mineral density loss. Chemotherapy may have an effect on
estrogen levels but may also have an effect on bone loss via direct cytotoxic effect on bone
cells.
Although there is data concerning BMD in patients who have received chemotherapy as children
and in men with prostate cancer, there is very little data concerning BMD in gynecologic
oncology patients who have received chemotherapy. Several different chemotherapeutic agents
have been incriminated in their effects on the bone mineral density. The alkylating drugs,
particularly Cytoxan, have been shown to decrease bone mineral density. Methotrexate and more
recently the taxanes appear to have the same effect. Since most chemotherapy today is given
as a combination, one or more of the cytoxic agents on the bone are included and therefore
this study will evaluate any postmenopausal women who has received chemotherapy.
Data collection:
Women participating in this study will undergo two scans: a Heel Scan which measures the bone
mineral density in the heel area and a DXA scan which measures bone mineral density in the
lumbar region of the spine and the hip. Both scans provide a T-score and a Z-score for the
subject.
density (BMD) probably due to endogenous estrogen production. After menopause, BMD decreases
rather rapidly particularly during the first years after natural menopause. Bone loss
typically is more rapid and severe in a premature induced menopause (surgical,
chemotherapeutically, or hormonal). The bone loss appears to be more rapid and at an earlier
age which advances bone age to a greater degree than actual age. Chemotherapeutically-induced
menopause accelerates this process by an average of 10 years. GnRH agonist in premenopausal
women causes amenorrhea in >95% with associated loss of both cortical and trabecular bone. In
women undergoing ovarian ablation therapy, losses in bone mass as high as 13% have been
reported in the first year of treatment. Premenopausal women who by treatment become
amenorrheic remain amenorrheic posttreatment in the vast majority of cases. Adjuvant therapy
for cancer can exaggerate bone mineral density loss. Chemotherapy may have an effect on
estrogen levels but may also have an effect on bone loss via direct cytotoxic effect on bone
cells.
Although there is data concerning BMD in patients who have received chemotherapy as children
and in men with prostate cancer, there is very little data concerning BMD in gynecologic
oncology patients who have received chemotherapy. Several different chemotherapeutic agents
have been incriminated in their effects on the bone mineral density. The alkylating drugs,
particularly Cytoxan, have been shown to decrease bone mineral density. Methotrexate and more
recently the taxanes appear to have the same effect. Since most chemotherapy today is given
as a combination, one or more of the cytoxic agents on the bone are included and therefore
this study will evaluate any postmenopausal women who has received chemotherapy.
Data collection:
Women participating in this study will undergo two scans: a Heel Scan which measures the bone
mineral density in the heel area and a DXA scan which measures bone mineral density in the
lumbar region of the spine and the hip. Both scans provide a T-score and a Z-score for the
subject.
Inclusion Criteria:
- Postmenopausal woman
- Diagnosed with breast or gynecological cancer
- Treated with chemotherapy
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
